Abstract: A motion sensor housing includes a base and a lens holder that is supported on the base. The motion sensor is disposed in the housing between the base and the lens holder so as to face the lens holder, and a frameless lens is supported on an outer surface of the lens holder in such a way that the lens provides the outermost surface of the housing. In addition, when the motion sensor housing is viewed facing the lens, the lens holder is not visible, and the outward-facing surface of the lens is free of edges, borders and/or discontinuities.

Abstract: Systems and methods for automatically obtaining cost-efficient access to a media content collection are provided. A user selection of a media content collection, which consists of a number of media assets, is received. A first price is determined for receiving access to the entire media content collection using a single transaction. For each media asset of the media content collection a set of providers of the media asset are identified, and the lowest price for receiving access to each media asset is determined. The lowest price for receiving access to each media asset of the media content collection is accumulated to determine a second price for receiving access to the media content collection using multiple transactions. The first and the second price are compared, and access to the media content collection is received based on this comparison.

Abstract: Methods and systems are disclosed herein for a media guidance application that adjusts modes based on actively determining an engagement level of a user. In such modes both the content presented and the interactions of a user that are recognized may be based on the level of engagement of the user.

Abstract: This invention relates generally to methods and pharmaceutical formulations useful in treating patients suffering from sleep apnea, including obstructive sleep apnea syndrome (OSAS). Treatment is effected by administering a carbonic anhydrase inhibitor to the patient in combination with an aldosterone antagonist. Formulations containing a therapeutically effective amount of a carbonic anhydrase inhibitor and a therapeutically effective amount of an aldosterone antagonist are provided as well.

Abstract: This disclosure relates generally to methods and pharmaceutical compositions useful in treating pulmonary hypertension. In one embodiment, for example, the disclosure provides a method for treating pulmonary hypertension comprising administering a therapeutically effective dose of a carbonic anhydrase inhibitor to a patient in need of treatment. The disclosure finds utility in the fields of medicine and pharmacology.

Abstract: A system that provides control over three-dimensional image content.

Abstract: Methods and systems described herein provide for visualizing content across different time segments of a media asset. Information about content within a particular time segment of a media asset is retrieved. This content information is generated by processing user-generated messages corresponding to the particular time segment. Content descriptors are generated based on the received content information corresponding to the particular time segment. A timeline is generated, independently of presenting a media asset, wherein the timeline visually associates content descriptors with their corresponding time segments of the media asset. When these content descriptors are selected by a user, the user-generated messages corresponding to the content descriptor at the corresponding time segment are displayed to the user.

Abstract: Methods and systems are described herein for a media guidance application that automatically corrects overruns during fast-access playback operations. For example, the media guidance application may base overrun corrections on the content of the media asset subject to the fast-access playback operation.

Abstract: Methods and systems are disclosed herein for a media guidance application that adjusts modes based on actively determining an engagement level of a user. In such modes both the content presented and the interactions of a user that are recognized may be based on the level of engagement of the user.

Abstract: Methods and systems are described herein for a media guidance application that automatically corrects overruns during fast-access playback operations. For example, the media guidance application may base overrun corrections on the attentiveness of the user.

Abstract: Methods and systems are disclosed herein for a media guidance application that adjusts modes based on actively determining an engagement level of a user. In such modes both the content presented and the interactions of a user that are recognized may be based on the level of engagement of the user.

Abstract: Methods and systems are disclosed herein for presenting information to groups of users using user optical devices that enable each user to view and share media content in a collaborative manner. For example, users using linked user optical devices may perceive a media playlist on a particular wall. The media playlist may then be modified (e.g., media assets may be added and/or removed) based on any of the users contacting the particular wall.

Abstract: A process for producing an acrylate product. The process comprises the step of providing a crude product stream comprising the acrylate product and an alkylenating agent. The process further comprises the step of separating at least a portion of the crude product stream to form an alkylenating agent stream and an intermediate product stream. The alkylenating agent stream comprises at least 1 wt % alkylenating agent and the intermediate product stream comprises acrylate product. The separating is performed in at least one column at an operating pressure ranging from 40 kPa to 80 kPa.

Abstract: The disclosed embodiments relate to, dosing regimens for the administration of topiramate, optionally in combination with one or more sympathomimetic agents such as phentermine. The dosing regimens can, for example, limit the exposure of subjects to topiramate, identify subjects who are unlikely to obtain a benefit from treatment with escalating dosages of topiramate (with or without the sympathomimetic agent, such as phentermine), or both, thereby reducing or eliminating harmful or intolerable side effects in subjects who are unlikely to respond to treatment and maximizing the therapeutic benefits from treatment in subjects who do respond.

Abstract: Methods and systems are provided for determining a suitable user input interface type based on a particular user. Specifically, a media guidance application determines a demographic category of a user, and based on that demographic category of the user, automatically selects a user input interface for manipulating media objects that is suitable for the user.

Abstract: In one embodiment, the invention is to a catalyst composition comprising vanadium and titanium. The catalyst composition further comprises ethylene glycol and citric acid. Preferably, the catalyst composition is substantially free of oxalic acid and lactic acid.

Abstract: In one embodiment, the invention is to a process for producing an acrylate product. The process comprises the step of reacting a reaction mixture comprising an alkanoic acid, an alkylenating agent, and oxygen over a catalyst and under conditions effective to form a crude acrylate product. Preferably, the reaction mixture comprises from 0.5 wt % to 10 wt % oxygen. The crude acrylate product comprises acrylate product and alkylenating agent. The process further comprises the step of separating at least a portion of the crude product to form at least one alkylenating agent stream and at least one purified acrylate product stream. The purified acrylate product stream comprises acrylate product.

Abstract: This disclosure relates generally to methods and pharmaceutical compositions useful in treating pulmonary hypertension. In one embodiment, for example, the disclosure provides a method for treating pulmonary hypertension comprising administering a therapeutically effective dose of a carbonic anhydrase inhibitor to a patient in need of treatment. The disclosure finds utility in the fields of medicine and pharmacology.